Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
Industry | Market Weight | YTD Return | |
---|---|---|---|
All Industries | 100.00% | 7.76% | |
Drug Manufacturers - General | 33.29% | 11.09% | |
Healthcare Plans | 13.22% | -0.71% | |
Medical Devices | 12.49% | 5.94% | |
Biotechnology | 11.70% | 2.76% | |
Diagnostics & Research | 10.73% | 1.24% | |
Medical Instruments & Supplies | 7.73% | 25.86% | |
Medical Care Facilities | 3.06% | 21.72% | |
Drug Manufacturers - Specialty & Generic | 2.76% | -0.66% | |
Medical Distribution | 2.51% | 20.46% | |
Health Information Services | 2.38% | 26.29% | |
Pharmaceutical Retailers | 0.12% | -63.98% |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
811.81 | 999.43 | 11.48% | | | | Buy | |
605.87 | 625.10 | 8.31% | | | | Buy | |
153.24 | 175.98 | 5.50% | | | | Buy | |
170.35 | 208.90 | 4.49% | | | | Buy | |
98.50 | 133.43 | 3.71% | | | | Buy | |
541.90 | 657.43 | 3.09% | | | | Buy | |
115.74 | 130.24 | 2.99% | | | | Buy | |
536.69 | 539.24 | 2.85% | | | | Buy | |
241.53 | 288.34 | 2.60% | | | | Buy | |
301.44 | 335.10 | 2.41% | | | | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
146.83 | 39.816B | 0.09% | | |
271.29 | 20.549B | 0.10% | | |
100.01 | 7.244B | 0.35% | | |
143.80 | 7.086B | 0.45% | | |
60.05 | 4.783B | 0.40% | |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
---|---|---|---|---|
213.67 | 45.697B | 0.30% | | |
90.12 | 45.697B | 0.30% | | |
135.66 | 20.549B | 0.10% | | |
97.91 | 14.589B | 0.80% | | |
97.56 | 14.589B | 0.80% | |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: ConvaTec Group PLC
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.
RatingPrice TargetAnalyst Report: Alcon Inc.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
RatingPrice TargetAnalyst Report: Novo Nordisk
Novo Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include Ozempic, Victoza, and insulin for diabetes; Wegovy and Saxenda for obesity; and treatments for rare blood and endocrine disorders. The company has approximately 71,880 employees.
RatingPrice TargetAnalyst Report: AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
RatingPrice Target